Results 121 to 130 of about 13,137 (165)
卡博替尼联合PD-L1单抗对黑色素瘤小鼠移植瘤的抑制作用机制
Zhongshan Daxue xuebao. Yixue kexue ban, 2019 【目的】探讨卡博替尼联合PD-L1单抗对恶性黑色素瘤小鼠皮下移植瘤生长的影响及作用机制。【方法】利用体外培养的小鼠黑色素瘤细胞B16-F10建立小鼠皮下移植瘤模型，成瘤后将小鼠随机分为盐水对照组、溶剂对照组、PD-L1单抗组、卡博替尼组和卡博替尼联合PD-L1单抗组（联合组）。观察肿瘤生长情况及每2d测量一次肿瘤体积。肿瘤体积达到2000mm3或是组间差距有显著统计学差异时定义为研究终点。达到研究终点后处死小鼠取材，流式细胞学检测肿瘤组织中浸润免疫细胞情况，包括CD4+、CD8 ...
祝保艳 +6 more
doaj
[Expert consensus on the management of off-label use of novel antineoplastic agents]. [PDF]
Zhejiang Da Xue Xue Bao Yi Xue BanPharmaceutical Management Professional Committee of Zhejiang Provincial Hospital Association +4 more
europepmc +1 more source
[Antitumor Study of Neoantigen-reactive T Cells Co-expressing IL-7 and CCL19 in Mouse Lung Cancer]. [PDF]
Zhongguo Fei Ai Za ZhiWu D +7 more
europepmc +1 more source
Zhongshan Daxue xuebao. Yixue kexue ban目的探讨冬虫夏草提取物对非小细胞肺癌（NSCLC）免疫治疗耐药的逆转作用。方法采用ELISA、流式细胞术、共培养实验检测冬虫夏草提取物对人源T淋巴细胞（JKT）细胞因子分泌、增殖和对肿瘤细胞杀伤活性的影响，进一步通过体内实验检测冬虫夏草提取物单独使用及联合程序性死亡配体-1（PD-L1）单抗对PD-L1耐药肺癌的疗效。结果冬虫夏草提取物可以增强JKT细胞的细胞因子γ-干扰素（IFN-γ）、肿瘤坏死因子α（TNF-α）、白细胞介素-2（IL-2）分泌，促进其细胞增殖（P=0.006 ...
卢敏源 +3 more
doaj +2 more sources
Zhongshan Daxue xuebao. Yixue kexue ban, 1989 用人新鲜胰腺癌组织免疫BALB/c小鼠,取脾细胞与小鼠骨髓瘤细胞Sp2/0-Agl4融合,获得了分泌抗人胰腺癌单克隆抗体的杂交瘤细胞株。本文重点报道以ABC免疫组织化学法检查YPC1单克隆抗体与人正常组织和肿瘤组织的反应性。结果表明YPC1单克隆抗体与16例被检测的胰腺癌组织发生反应。其中9例(56.3％)呈强阳性反应,与23种正常组织中的10种(43.5％)以及19种非胰腺肿瘤中的8种(42.1％)有不同程度的交叉反应,但多数反应较弱。本研究提示以新鲜人体肿瘤组织作为免疫原制备单克隆抗体是简便可行的 ...
doaj
[Single extract of Forsythia Suspense versus the prepared drug in pieces: comparison of their anti-inflammatory, antitumor and antibacterial effects in zebrafish]. [PDF]
Nan Fang Yi Ke Da Xue Xue BaoGuo X +8 more
europepmc +1 more source
Zhongshan Daxue xuebao. Yixue kexue ban, 1996 应用增殖细胞核抗原（ＰＣＮＡ）单克隆抗体免疫组化方法检测４０例骨肿瘤切片。结果表明，各亚型和各组织学分级的骨肉瘤和骨巨细胞瘤ＰＣＮＡ阳性率无统计学意义。骨巨细胞瘤组织中的单核基质细胞和多核巨细胞中的部分细胞核呈ＰＣＮＡ阳性，提示单核基质细胞是肿瘤性细胞，而部分多核巨细胞是由这些肿瘤性单核基质细胞融合而来。软骨肉瘤ＰＣＮＡ阳性率明显低于骨肉瘤的软骨母细胞型。
doaj
[ORY-1001 inhibits glioblastoma cell growth by downregulating the Notch/HES1 pathway via suppressing lysine-specific demethylase 1 expression]. [PDF]
Nan Fang Yi Ke Da Xue Xue BaoYang H, Xiang Y, Tan T, Lei Y.
europepmc +1 more source
[Clinical Progress and Prospects of mRNA Tumor Drugs]. [PDF]
Sichuan Da Xue Xue Bao Yi Xue BanChen J +5 more
europepmc +1 more source
[Heterogeneity of tumor-associated macrophages and precision targeting strategies in hepatocellular carcinoma]. [PDF]
Zhonghua Gan Zang Bing Za ZhiHuang K, Zhang GQ.
europepmc +1 more source